Suven Life Sciences Limited

Rajesh Kumar Badange

Venkateswarlu Jasti

Ramakrishna Nirogi

Anil Karbhari Shinde

Abdul Rasheed Mohammed

Pradeep Jayarajan

Kumar Bojja

Rama Sastri Kambhampati

Gopinadh Bhyrapuneni

Ishtiyaque Ahmad

Vijay Sidram Benade

Ramkumar Subramanian

Vinod Kumar Goyal

Santosh Kumar Pandey

Rambabu Namala

Renny Abraham

Veena Reballi

Anil Kashinath Chindhe

Mohamad Sadik Abdulhamid Mulla

Raghava Choudary Palacharla

Jagadeesh Babu Thentu

Mohamad Sadik Mulla

The present invention relates to substituted heterocyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes the method of making such compounds, pharmaceutical compositions comprising such compounds and their use in the treatment of central nervous system disorders.

Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.

Substituted azacycles as muscarinic M1 receptor positive allosteric modulators

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

Muscarinic M1 receptor positive allosteric modulators

The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof. 

Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists

The present invention relates to novel sulfone compounds as 5-HTreceptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HTreceptor functions.

Sulfone compounds as 5-HT6 receptor ligands

Growing community of inventors

Hyderabad Telangana, India

Rajesh Kumar Badange